In Organovo's financial conference call today, Keith Murphy, Organovo’s chief executive officer, indicated that “response to the exVive3D Human Liver Tissue has been strong, and in line with our expectations. We continue to expect this tissue to grow into the tens of millions in annual revenue, and that it has $100M+ revenue potential.
The fact that recent data shows that the exVive3D Human Liver Tissue clearly demonstrated the toxicity of another drug missed during preclinical studies, troglitazone (Rezulin), which exhibited a clear response by causing a statistically significant drop in liver function in our liver tissue at 7 days, provides the potential for our commercial penetration to accelerate even faster.”